[go: up one dir, main page]

FI953533L - Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena - Google Patents

Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena Download PDF

Info

Publication number
FI953533L
FI953533L FI953533A FI953533A FI953533L FI 953533 L FI953533 L FI 953533L FI 953533 A FI953533 A FI 953533A FI 953533 A FI953533 A FI 953533A FI 953533 L FI953533 L FI 953533L
Authority
FI
Finland
Prior art keywords
active ingredient
system containing
therapeutic system
transdermal therapeutic
containing galantamine
Prior art date
Application number
FI953533A
Other languages
English (en)
Swedish (sv)
Other versions
FI113744B (fi
FI953533A0 (fi
Inventor
Thomas Hille
Lothar Deurer
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of FI953533L publication Critical patent/FI953533L/fi
Publication of FI953533A0 publication Critical patent/FI953533A0/fi
Application granted granted Critical
Publication of FI113744B publication Critical patent/FI113744B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI953533A 1993-01-23 1995-07-21 Menetelmä galantamiinia vaikuttavana ainesosana sisältävän transdermaalisen terapeuttisen järjestelmän valmistamiseksi FI113744B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4301783A DE4301783C1 (de) 1993-01-23 1993-01-23 Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE4301783 1993-01-23
EP9400054 1994-01-10
PCT/EP1994/000054 WO1994016707A1 (de) 1993-01-23 1994-01-10 Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil

Publications (3)

Publication Number Publication Date
FI953533L true FI953533L (fi) 1995-07-21
FI953533A0 FI953533A0 (fi) 1995-07-21
FI113744B FI113744B (fi) 2004-06-15

Family

ID=6478781

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953533A FI113744B (fi) 1993-01-23 1995-07-21 Menetelmä galantamiinia vaikuttavana ainesosana sisältävän transdermaalisen terapeuttisen järjestelmän valmistamiseksi

Country Status (26)

Country Link
US (1) US5700480A (fi)
EP (1) EP0680325B1 (fi)
JP (1) JPH08505632A (fi)
KR (1) KR100300477B1 (fi)
AT (1) ATE216240T1 (fi)
AU (1) AU679032B2 (fi)
CA (1) CA2153572C (fi)
CZ (1) CZ287053B6 (fi)
DE (2) DE4301783C1 (fi)
DK (1) DK0680325T3 (fi)
ES (1) ES2176234T3 (fi)
FI (1) FI113744B (fi)
HR (1) HRP940028B1 (fi)
HU (1) HU221165B1 (fi)
IL (1) IL108235A (fi)
MY (1) MY109926A (fi)
NO (1) NO307497B1 (fi)
NZ (1) NZ259857A (fi)
PH (1) PH31473A (fi)
PL (1) PL175083B1 (fi)
PT (1) PT680325E (fi)
SI (1) SI9400024A (fi)
SK (1) SK281339B6 (fi)
WO (1) WO1994016707A1 (fi)
YU (1) YU48607B (fi)
ZA (1) ZA94414B (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU732803B2 (en) * 1996-01-17 2001-05-03 National Starch And Chemical Investment Holding Corporation Adhesives resistant to skin-penetration enhancers
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
DE69730988T2 (de) * 1996-07-15 2006-02-23 Alza Corp., Mountain View Neue formulierungen zur transdermalen verabreichung von fluoxetinacetat und fluoxetinmaleat
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
EE04996B1 (et) * 1998-12-24 2008-04-15 Janssen Pharmaceutica N.V. Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
US6241998B1 (en) 1999-02-02 2001-06-05 Acutek International Dermatological patch
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
WO2001026648A1 (en) * 1999-10-13 2001-04-19 Senju Pharmaceutical Co., Ltd. Ophthalmic adhesive preparations for percutaneous absorption
EP1237524A4 (en) 1999-12-10 2004-06-30 Bonnie M Davis GALANTHAMINE AND LYCORAMINE ANALOGS FOR USE AS MODULATORS OF NICOTINIC RECEPTORS
CN1293196C (zh) * 2000-05-26 2007-01-03 大日本住友制药株式会社 具有副作用降低的特性的新型重组腺病毒载体
FR2814368B1 (fr) * 2000-09-26 2004-05-07 Pf Medicament Preparation pharmaceutique a base d'oxans
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
PT1895994E (pt) * 2005-05-13 2010-12-03 Alza Corp Sistema de administração de medicamentos de camada múltipla com barreira contra o fluxo de material do reservatório
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102008059054A1 (de) 2008-11-26 2010-05-27 Otto Bock Pur Life Science Gmbh Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
ES2528650T3 (es) 2010-11-17 2015-02-11 Hexal Ag Sistema terapéutico transdérmico que comprende buprenorfina
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
MX2022005168A (es) 2019-11-06 2022-06-08 Smartech Topical Inc Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239318A (en) * 1983-04-27 1988-07-19 Hans R. Hoffmann Pharmaceutical product preferably in medical bandage form and process for producing them
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3843239C1 (fi) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
EP0515301A3 (en) * 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors

Also Published As

Publication number Publication date
JPH08505632A (ja) 1996-06-18
PL309603A1 (en) 1995-10-30
NO952907D0 (no) 1995-07-21
PT680325E (pt) 2002-09-30
NO307497B1 (no) 2000-04-17
IL108235A0 (en) 1994-04-12
SK88995A3 (en) 1996-05-08
MY109926A (en) 1997-09-30
PH31473A (en) 1998-11-03
DK0680325T3 (da) 2002-08-05
CZ184295A3 (en) 1996-01-17
DE59410103D1 (de) 2002-05-23
SI9400024A (en) 1994-09-30
AU679032B2 (en) 1997-06-19
NZ259857A (en) 1996-03-26
SK281339B6 (sk) 2001-02-12
FI113744B (fi) 2004-06-15
NO952907L (no) 1995-07-21
US5700480A (en) 1997-12-23
WO1994016707A1 (de) 1994-08-04
DE4301783C1 (de) 1994-02-03
CZ287053B6 (en) 2000-08-16
FI953533A0 (fi) 1995-07-21
ZA94414B (en) 1994-08-31
HRP940028A2 (en) 1996-06-30
CA2153572C (en) 2006-01-03
ATE216240T1 (de) 2002-05-15
YU48607B (sh) 1998-12-23
YU2694A (sh) 1996-10-18
HUT72643A (en) 1996-05-28
HRP940028B1 (en) 2000-02-29
KR960700060A (ko) 1996-01-19
EP0680325B1 (de) 2002-04-17
CA2153572A1 (en) 1994-08-04
IL108235A (en) 1996-10-31
EP0680325A1 (de) 1995-11-08
KR100300477B1 (ko) 2001-10-22
PL175083B1 (pl) 1998-10-30
AU5881794A (en) 1994-08-15
HU221165B1 (en) 2002-08-28
HU9501928D0 (en) 1995-09-28
ES2176234T3 (es) 2002-12-01

Similar Documents

Publication Publication Date Title
FI953533L (fi) Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena
DE69113205D1 (de) Transdermales therapeutisches System.
FI955259L (fi) Estradiolia sisältävä transdermaalinen terapeuttinen systeemi
FI961282L (fi) Transdermaalinen terapeuttinen systeemi, jossa on asetyylisalisyylihappo vaikuttavana aineena
FI954990L (fi) Aktiiviainetta sisältävä transdermaalinen valmiste
KR970006279A (ko) 약제학적 활성 성분으로서의 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물
FI973320A7 (fi) Kiinteitä aktiiviainetta sisältäviä valmisteita
ATE98480T1 (de) Arzneimittelformulierungen.
FI960556L (fi) Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä
DE59402194D1 (de) Fungizide Wirkstoffkombinationen
ITMI961152A0 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
FI895681A0 (fi) Farmaceutisk komposition foer systemisk transdermal tillfoersel.
DE59408221D1 (de) Fungizide Wirkstoffkombinationen
DE69218932D1 (de) Transdermale therapeutische Formulierung
MX9203602A (es) Administracion iontoforetica mejorada de farmacos.
FI961437L (fi) Vaikuttavan aineen luovuttava systeemi
FI894688A0 (fi) Flytande oralt tagbart terapeutiskt system.
ITRM920412A0 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico.
FR2710915B1 (fr) Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
FI925778A0 (fi) Farmaceutiskt aktiva bensokinazolinfoereningar
FI950165L (fi) Ihon läpäisevä terapeuttinen järjestelmä, jossa vaikuttavana aineena on 17-beta-estradioli (vedetön)
FI954497A7 (fi) Aktiivista ainetta sisältävä laastari estradiolin vapauttamiseksi ihoo n
FI875098A7 (fi) Transdermaalinen terapeuttinen systeemi.
FI962220L (fi) Transdermaalinen terapeuttinen järjestelmä
NO870533L (no) Terapeutisk aktive 3-alkoksy-2-aminopropylaminer.

Legal Events

Date Code Title Description
MM Patent lapsed